LUND, Sweden, July 25, 2024 /PRNewswire/ -- Immunovia (Nasdaq
Stockholm: IMMNOV), the pancreatic cancer diagnostics company,
today presented detailed discovery study results for the company's
next-generation early detection test for pancreatic cancer at the
PancreasFest 2024 Annual Meeting (abstract #P33).
PancreasFest is an annual conference of physicians and
translational researchers with special interest in the pancreas who
convene to find new ways to improve the care of patients with
pancreatic disease, including pancreatic cancer. It is organized by
the Collaborative Alliance for Pancreatic Education and
Research. Abstracts submitted to this medical conference
undergo a rigorous peer-review and selection process in which only
a subset of studies are chosen for presentation at the meeting.
Results presented at PancreasFest reflect a detailed scientific
presentation of the initial positive data the company shared in a
7 November 2023 press release.
The discovery study, the most comprehensive pancreatic cancer
proteomics study done to date, identified 15 promising protein
biomarkers that were shown to strongly correlate with the presence
of pancreatic ductal adenocarcinoma (PDAC). These protein
biomarkers demonstrated the ability to differentiate PDAC cases
from non-PDAC controls. Over 3,000 proteins were evaluated in 329
blood samples from Stage 1 and II PDAC and non-PDAC matched control
patients using Olink multiplex technology and conventional
immunoassays.
"We are honored to have been chosen to present the discovery
study results at this important conference. We look forward to
discussing the detailed study data and receiving scientific and
clinical insights from this key group of physicians and researchers
who are experts in pancreatic cancer," said Norma Palma PhD,
Vice President of Clinical and Medical Affairs at Immunovia.
For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
+46 709 11 56 08
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase
survival rates for patients with pancreatic cancer through early
detection. Immunovia is focused on the development and
commercialization of simple blood-based testing to detect proteins
and antibodies that indicate a high-risk individual has developed
pancreatic cancer.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups to make its test
available to individuals at increased risk for pancreatic
cancer.
USA is the world's largest
market for detection of pancreatic cancer. The company estimates
that in the USA, 1.8 million
individuals are at high-risk for pancreatic cancer and could
benefit from annual surveillance testing.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com
CONTACT:
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-presents-data-from-discovery-study-at-2024-pancreasfest-medical-conference,c4018507
The following files are available for download:
https://mb.cision.com/Main/13121/4018507/2926549.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.co.uk/news-releases/immunovia-presents-data-from-discovery-study-at-2024-pancreasfest-medical-conference-302206926.html